Swiss biotech AC Immune has said that its vaccine-like alpha-synuclein-targeted immunotherapy has shown promise in slowing ...

Inhibiting prolactin receptor (PRLR) signaling with the ABS-201 anti-PRLR antibody promotes human hair follicle growth ex vivo Human ex vivo data validate ABS-201’s potential to reverse follicular ...

Prior to joining Serina, Dr. Thomas served in progressive scientific leadership roles at Mersana Therapeutics, where during his 13 years he played a pivotal part in building out their discovery ...

China's first national-level onshore shale oil demonstration zone has reached its annual crude output target of 1.7 million ...

The University of Delaware’s David Martin, Karl W. and Renate Böer Chair in the Department of Materials Science and Engineering, has been named to the National Academy of Inventors (NAI) 2025 Class of ...

Allied Market Research published a report, titled, "Immunostimulant Market by Product Type (Vaccines, Colony Stimulating ...

Discusses ABS-201 Program and Clinical Approach for Androgenetic Alopecia December 11, 2025 10:00 AM ESTCompany ...

Igyxos Biotherapeutics is dedicated to developing innovative treatments for infertility in both men and women. Its lead asset, IGX12, is a first-in-class potentiating monoclonal antibody designed to ...

Golcadomide, a first-in-class, oral CELMoD (cereblon E3 ligase modulator), has shown compelling activity as a monotherapy and ...

ORLANDO -- Adding four monthly infusions of novel ianalumab helped adults with primary immune thrombocytopenia (ITP) achieve durable disease control in the second-line setting while stopping daily ...

UPPSALA, SE / ACCESS Newswire / December 10, 2025 / Senzime (STO:SEZI)(OTCQX:SNZZF) - Senzime AB (publ) today announced the launch of the latest series of innovative features for its next-generation ...

Rondo Therapeutics begins patient dosing in phase 1/1b trial of RNDO-564 in adults with r/r locally advanced or metastatic urothelial carcinoma: Hayward, California Saturday, Dece ...